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Abstract
Background: The aim was to characterise the sociodemographic, general health and polymyalgia rheumatica
(PMR)-specific features of participants in a large inception cohort of patients with PMR diagnosed in UK primary care.
Methods: Patients (n = 739) with a new diagnosis of PMR were referred into the study and mailed a questionnaire
detailing their general health and sociodemographic characteristics in addition to the symptoms of and treatment
for PMR. Characteristics of responders and non-responders were compared and descriptive statistics were used to
characterise the health of the cohort.
Results: A total of 654 individuals responded to the questionnaire (adjusted response 90.1 %). Responders and
non-responders were similar in age, gender and deprivation (based on postcode). The mean (standard deviation) age
of the recruited cohort was 72.4 (9.3) years; 62.2 % were female. The sample reported high levels of pain and stiffness
(8 out of 10 on numerical rating scales) and reported stiffness that lasted throughout the day. High levels of functional
impairment, fatigue, insomnia and polypharmacy were also reported. Overall, women reported worse general and
PMR-specific health than did men.
Conclusions: This first primary care cohort of patients with incident PMR is similar in demographic terms to cohorts
recruited in secondary care. However, the extent of symptoms, particularly reported stiffness, is higher than has been
described previously. Given the majority of patients with PMR are exclusively managed in primary care, this cohort
provides important information on the course of PMR in the community that will help clinicians managing this painful
and disabling condition.
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Background
Polymyalgia rheumatica (PMR) is a common inflamma-
tory rheumatic condition in those over the age of 50,
with an estimated lifetime prevalence of 2.4 % in women
and 1.7 % in men [1]. Classic presentation involves rapid
onset of bilateral pain and stiffness in the shoulders and
hip girdle, usually in combination with raised inflamma-
tory markers. Although common, it has received rela-
tively little research attention, particularly in the primary
care setting, where the majority of patients are diag-
nosed and managed [2, 3].
To date, our understanding of the epidemiology of
PMR is not as advanced as for other inflammatory
rheumatological conditions. Those diagnosed with PMR
are more likely to be female and have an average age at
diagnosis of approximately 72 years [4]. PMR is more
prevalent at more northerly latitudes [5, 6] and is fre-
quently associated with giant cell arteritis (GCA) with
between 16 and 21 % of patients with PMR having evi-
dence of GCA and up to 60 % of patients with GCA
having symptoms of PMR [7]. Recent studies have iden-
tified increased risk of vascular disease [8] and cancer
diagnosis [9] following a diagnosis of PMR, though the
mechanisms behind these associations remain uncertain.
The PMR Cohort Study was established to investigate
the primary care epidemiology of PMR. In this inception
cohort of general practitioner (GP)-diagnosed PMR, pa-
tients are followed via postal surveys and medical re-
cords for two years post-PMR diagnosis. Medical
records are also available for the two years prior to diag-
nosis. This paper presents data from the baseline survey
phase of the study, describing the recruited sample in
terms of sociodemographic data, general health and
disease-specific characteristics.
Methods
Study design
The PMR Cohort Study is an inception cohort of people
diagnosed with PMR in general practice. The methods
of the study have been described in detail elsewhere
[10]. Briefly, participants were referred from 382 general
practices across England between June 2012 and June
2014. When seeing a potentially eligible patient, an elec-
tronic prompt alerted the GP to the study as specific dis-
ease codes were entered into the patient record,
reminding them of the patients’ eligibility and the British
Society for Rheumatology (BSR) guidelines for diagnos-
ing PMR. In practices without electronic prompts in
place, laminated cards with these details were placed, as
an aide memoire, in consulting rooms.
Study packs, including written copies of the BSR PMR
clinical guidelines were provided for each practice.
General practitioners (GPs) referred patients who pro-
vided verbal consent to receive more information into
the study via secure fax or email when they made a new
diagnosis of PMR (no previous Read-coded consultation
in the last three years). Participants were then sent a
baseline questionnaire. Participants who did not respond
within three weeks were sent a reminder questionnaire.
Response to the baseline questionnaire implied consent
to be followed up via postal survey at six further time
points over two years (1, 4, 8, 12, 18 and 24 months).
Participants were also asked whether they consented to
the linkage of their survey data to their primary care
medical records and nationally held registers. This study
describes data from the baseline phase of the study only.
Baseline data collection
The baseline questionnaire collected information on
PMR symptoms at the time of diagnosis, treatments re-
ceived for PMR, general health, lifestyle, function, socio-
demographics and participants’ views on the causes of
their PMR.
Sociodemographic information
The date of birth (used to calculate age), gender and
postcode (used to calculate indices of multiple
deprivation [11] of all patients referred into the study by
their GP were available from the referral form. The base-
line questionnaire also collected information on current
employment status (employed, retired, unemployed,
housewife/husband, sick or other), ethnicity (white,
Asian/Asian British, black/African/Caribbean/African/
black British, mixed or other), socioeconomic class based
on current or last job title (“High managerial, administra-
tive and professional”, “Intermediate” or “Routine and
manual”, according to the Office for National Statistics
criteria [12], whether the participant lived alone or not
and marital status (married, separated, divorced, widowed,
cohabiting or single).
General health, lifestyle and function measures
General health-related quality of life was assessed using
the descriptive component of the Euroqol-5D (EQ-5D)
[13]. The five items of this questionnaire are combined
to create an index where 1 is considered perfect health
and 0 is considered to be representative of death or un-
consciousness. The worst health state on this index is
valued at -0.59 (i.e. worse than death).
Function in activities of daily living in the past week
was assessed using the modified Health Assessment
Questionnaire (mHAQ) [14, 15]. Scores on this 8-item
instrument range from 0 to 3, with a score of less than
0.3 considered to represent normal functioning [16].
Fatigue in the past week was assessed using the 13-
item Functional Assessment of Chronic Illness Therapy
(FACIT)-fatigue questionnaire that has been shown to
be valid and reliable for use with patients with systemic
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lupus erythematosus. Scores on the questionnaire range
from 0 to 52 and higher scores indicate less fatigue. In
the general US population aged 18 years and over, the
mean score on this instrument has been shown to be
40.1 (SD 10.4) [17].
Insomnia in the previous two weeks was assessed
using the 7-item Insomnia Severity Index (ISI), with
individuals classified as having no clinically significant
insomnia, subthreshold insomnia, clinical insomnia
(moderate severity) or clinical insomnia (severe).
Anxiety and depression in the previous two weeks
were assessed using the 7-item Generalised Anxiety
Disorder (GAD) questionnaire [18] and the 8-item
Patient Health Questionnaire [19], respectively. Anxiety
was classified as none (score 0–4), mild (5–9), moderate
(10–14) or severe (15–21). Depression was classified as
none (score 0–4), mild (5–9), moderate (10–14), moder-
ately severe (15–19) or severe (20–24). Participants were
also asked whether they had someone they could rely on
for emotional and practical support.
Smoking status (never smoked, ex-smoker or current
smoker) and frequency of alcohol consumption (daily or
almost daily, 3–4 times a week, 1–2 times a week, 1–3
times a month, special occasions or never) were reported
by responders, along with height and weight, which were
used to calculate body mass index (BMI).
Symptoms of and treatments for PMR
Participants reported the levels of pain and stiffness they
were experiencing when their GP diagnosed them with
PMR on a 0 to 10 scale where 0 was no pain/stiffness
and 10 was “pain as bad as can be”/“very severe” stiff-
ness, by circling the number corresponding to the level
of pain/stiffness as appropriate. They were also asked to
check boxes indicating which times of day they experi-
enced stiffness (none, morning, lunchtime, afternoon,
early evening, late evening or during the night), the
duration of any morning stiffness (none, 1–15 minutes,
16–45 minutes, 46–60 minutes or >1 hour) and whether
they could raise their arms above their head when they
were diagnosed with PMR. Participants were also asked
to report whether they used prednisolone or a range of
other medications for their PMR.
Statistical analyses
Responders were compared to non-responders by age,
gender and tertile of deprivation score using basic de-
scriptive statistics. The sociodemographic data, general
health and lifestyle and PMR-specific symptoms and
treatments of the sample were described using means
and standard deviations (SD), medians and interquartile
ranges (IQR) and frequencies and percentages, as appro-
priate. The characteristics of the sample were compared
between men and women using the chi-square, rank
sum or t test as applicable. Levels of pain and stiffness
were compared graphically and by calculating correl-
ation coefficients.
Results
Response to the survey
There were 739 people referred into the study. Three of
these were duplicate patients, two had died, four had in-
correct address information, and four were otherwise in-
eligible. This left an eligible sample of 726, of whom 654
responded to the baseline questionnaire (adjusted re-
sponse rate 90.1 %). The age and gender of responders
(mean (standard deviation) age 72.4 years (9.3), 62.2 %
female) and non-responders (mean (standard deviation)
age 72.6 years (10.0), 62.5 % female) were similar overall,
although non responders were more likely to be in the
highest tertile of deprivation (32.3 % responders vs
38.9 % non-responders).
Sociodemographic characteristics
The majority of the sample were retired (n = 513,
79.9 %), with only 77 (11.9 %) reporting themselves to
be employed. Almost all of the sample identified them-
selves as being of white ethnicity (n = 640, 98.2 %). Ap-
proximately a third of the sample had or had previously
held higher managerial, administrative or professional
occupations, 28 % had intermediate occupations and
40 % had routine occupations. The majority of people
reported that they did not live alone (n = 467, 71.6 %)
and 412 (63.4 %) reported that they were married, and
143 (22 %) were widowed.
General health and lifestyle characteristics
The median EQ-5D descriptive component score was
0.73 (IQR 0.59, 0.85) and was higher in men than in
women (Table 1). The median mHAQ score was 0.40
(IQR 0.0, 1.0), with a higher score in women than in
men (0.5 (0.0, 1.0) vs 0.38 (0.0, 0.9); p = 0.0434). The
mean FACIT-Fatigue score was 33.9 (SD 12.4), with
women reporting being more fatigued than men (32.0
(12.8) vs 37.0 (10.8); p < 0.0001). Approximately 24 % of
the sample were considered to have clinical insomnia,
13 % anxiety (moderate or severe) and 22 % depression
(moderate, moderately severe or severe). The prevalence
of all of these symptoms was higher in women than in
men (p < 0.0001).
Current smoking was reported by 6.2 % (n = 40) of the
sample, with 44.5 % reporting previously having smoked.
Men were more likely to have smoked previously than
women. A quarter of the sample reported drinking three
times a week or more, and 45.3 % (n = 295) reported
never drinking or drinking only on special occasions.
More frequent drinking was more common in men than
in women.
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Table 1 General health characteristics of responders
All Female Male P value
EQ-5D descriptive component scorea (median, IQR) 0.73 (0.59, 0.85) 0.69 (0.52,0.81) 0.76 (0.62, 1.0) 0.0008
mHAQ (median, IQR) 0.40 (0.0, 1.0) 0.5 (0.0, 1.0) 0.38 (0.0, 0.9) 0.0434
FACIT-Fatigue (mean, SD)a 33.9 (12.4) 32.0 (12.9) 37.0 (10.8) <0.0001
Insomnia (ISI) (n, %) 0.003
No clinically significant insomnia 244 (39.6) 130 (33.9) 114 (48.9)
Subthreshold insomnia 227 (36.9) 151 (39.4) 76 (32.6)
Clinical insomnia (moderate severity) 112 (18.2) 78 (20.4) 34 (14.6)
Clinical insomnia (severe) 33 (5.4) 24 (6.3) 9 (3.9)
Anxiety (GAD–7) (n, %) <0.0001
None (0–4) 397 (65.0) 220 (58.4) 177 (75.6)
Mild (5–9) 134 (21.9) 93 (24.7) 41 (17.5)
Moderate (10–14) 49 (8.0) 41 (10.9) 8 (3.4)
Severe (15–21) 31 (5.1) 23 (6.1) 8 (3.4)
Depression (PHQ-8) (n, %) <0.0001
None (0–4) 318 (52.7) 171 (46.3) 147 (62.8)
Mild (5–9) 153 (25.4) 93 (25.2) 60 (25.6)
Moderate (10–14) 71 (11.8) 56 (15.2) 15 (6.4)
Moderately severe (15–19) 38 (6.3) 30 (8.1) 8 (3.4)
Severe (20–24) 23 (3.8) 19 (5.2) 4 (1.7)
Smoking status (n, %) <0.0001
Never smoked 318 (49.3) 223 (55.9) 95 (38.6)
Ex-smoker 287 (44.5) 153 (38.4) 134 (54.5)
Current smoker 40 (6.2) 23 (5.8) 17 (6.9)
Frequency of alcohol consumption (n, %) <0.0001
Daily or almost daily 82 (12.6) 26 (6.4) 56 (22.8)
3–4 times a week 82 (12.6) 42 (10.3) 40 (16.3)
1–2 times a week 113 (17.3) 56 (13.8) 57 (23.2)
1–3 times a month 80 (12.3) 52 (12.8) 28 (11.4)
Special occasions 185 (28.4) 141 (34.7) 44 (17.9)
Never 110 (16.9) 89 (21.9) 21 (8.5)
Body mass index (n, %) 0.001
< 25 kg/m2 221 (33.9) 128 (33.2) 83 (35.0)
25.0–29.9 kg/m2 251 (40.3) 139 (36.0) 112 (47.3)
30.0–34.9 kg/m2 100 (16.1) 69 (17.9) 31 (13.1)
≥ 35 kg/m2 61 (9.8) 50 (13.0) 11 (4.6)
Count on someone to provide emotional support (n, %) 0.009
Yes 553 (85.2) 355 (87.7) 198 (81.2)
No 35 (5.4) 23 (5.7) 12 (4.9)
No need 61 (9.4) 27 (6.7) 34 (13.9)
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One third of the sample (n = 221, 33.9 %) had self-
reported BMI under <25 kg/m2 and 161 (25.9 %) had
BMI >30 kg/m2. Being overweight (BMI ≥25 to <30 kg/
m2 was more common in men and obesity (BMI ≥30 kg/
m2) was more common in women).
The majority of people reported having someone to
provide emotional (n = 553, 85.2 %) or practical support
(519, 79.7 %) or not to need this sort of support (emo-
tional: n = 61 (9.4 %); practical: n = 100 (15.4 %)).
Women were more likely to desire and have access to
both types of help (for emotional support p = 0.009; for
practical support p < 0.0001).
Symptoms of PMR
The median (IQR) scores were 8 (7, 9) for pain and 8 (7, 9)
for stiffness. In both of these ratings, women reported
higher scores than men (Table 2) (for pain p = 0.0005; for
stiffness p = 0.0049). There was strong correlation between
pain and stiffness scores in both men (r = 0.6671) and
women (ρ = 0.5766) (Fig. 1).
Almost all participants reported stiffness in the
morning (n = 619, 95.2 %) with more than half also
reporting stiffness at all other times of day. A similar
proportion of men and women reported daytime stiff-
ness, with women reporting more stiffness during the
night (p = 0.047). Duration of morning stiffness was
generally reported to be more than an hour (n = 454,
71.2 %), with only 17.6 % reporting stiffness in the
morning lasting 45 minutes or less. Stiffness duration
was similar in men and women. Approximately two
thirds of people (n = 413, 64 %) reported being unable
to raise their arms above their head when they were
diagnosed with PMR, and 7.1 % (n = 46) reported that
they did not know. There was no significant differ-
ence between genders in reported ability to do this
task (p = 0.101).
Treatments for PMR
Use of prednisolone among survey respondents was al-
most universal (n = 626, 96.9 %). Use of other medica-
tions for PMR was also prevalent, with 37.9 % (n = 248)
reporting using paracetamol and 21 % (n = 137) report-
ing use of combination analgesia. Both of these medica-
tions were more common in women than in men
(paracetamol: 43.2 % vs 29.2 %; combination analgesia:
23.6 % vs 16.6 %). Participants also reported using non-
steroidal anti-inflammatories (n = 69, 10.6 %), strong
prescription painkillers (e.g. tramadol) (n = 86, 13.2 %)
(again this was more common in women (15.2 % vs
9.7 %)) and alternative therapies (e.g. homeopathy, acu-
puncture, herbal medicine) (n = 26, 4.0 %). Patients also
attributed use of gastro-protective (n = 332, 50.8 %),
osteoporosis (n = 170, 26.0 %) and calcium and vitamin
D (n = 304, 46.5 %) treatments to their PMR: 55 partici-
pants (8.4 %) reported taking anti-depressants in relation
to their PMR. Use of osteoporosis treatments and anti-
depressants were more common in women than in men
(osteoporosis treatment: 29.2 % vs 42.5 %; anti-
depressants: 11.6 % vs 3.2 %).
Discussion
Polymyalgia rheumatica is largely managed in primary
care [2, 3], yet to date there is a paucity of research evi-
dence from patients managed in this setting. As such,
clinicians rely on data generated in secondary care that
can be challenging to generalise to patients in the com-
munity, who may have less severe disease [20] and dif-
ferent prognostic trajectories. This study is the first to
characterise a large primary care sample of PMR patients
at the time of their diagnosis, thereby providing an unse-
lected and more representative PMR population.
Participant demographics seen in this inception cohort
are similar to those recruited from hospital populations,
with an average age at disease onset of approximately
72 years and around two thirds of participants being
female. Also in keeping with existing evidence on the
propensity of this condition to affect those of Northern
European descent, the cohort self-identifies almost en-
tirely as being of white ethnicity, despite having re-
cruited from a large range of geographical areas with
differing levels of ethnic diversity. Similarly to a previous
population study, there is a broad spread of occupational
class across the sample [21]. This suggests that hospital
PMR cohorts have similar demographics to this unse-
lected primary care sample, providing some reassurance
as to the accuracy of GP diagnosis for participants in
this cohort. However, unlike the classic description of
stiffness predominantly in the morning, within this co-
hort stiffness was severe and diurnal, with more than
60 % also reporting stiffness in the evening and the
Table 1 General health characteristics of responders (Continued)
Count on someone to provide practical support (n, %) <0.0001
Yes 519 (79.7) 347 (85.5) 172 (70.2)
No 32 (4.9) 18 (4.4) 14 (5.7)
No need 100 (15.4) 41 (10.1) 59 (24.1)
aHigh score indicates better functioning. EQ-5D EuroQoL 5 dimensions, mHAQ-D Modified Health Assessment Questionnaire Disability Index, FACIT Functional Assessment
of Chronic Illness Therapy, ISI Insomnia Severity Index, GAD-7 Generalised Anxiety Disorder 7-item questionnaire, PHQ-8 8-item Patient Health Questionnaire
Muller et al. Arthritis Research & Therapy  (2016) 18:200 Page 5 of 9
majority also describing night-time stiffness. In part this
may reflect questionnaire design, in that participants
were asked specifically about the presence of stiffness at
other times of the day, although as qualitative data in
both patients with rheumatoid arthritis [22] and PMR
[23] highlights that stiffness may be more varied and
complex than is usually reported and is present at vari-
ous times of day, not just in the morning. Given that
stiffness is considered key as part of the core domain set
for PMR by Outcome Measures in Rheumatology
(OMERACT) [24], we felt that timing of stiffness war-
ranted further exploration within the cohort.
The reported high levels of pain and stiffness that
persisted throughout the day (especially in women) may
explain the high proportion reporting use of pain killers
and non-steroidal anti-inflammatory drugs in addition to
prednisolone, especially in women. Furthermore, the
greater severity of symptoms in women is in concord-
ance with a previous case series from a tertiary referral
clinic [25].
Table 2 Polymyalgia rheumatica (PMR)-related characteristics of responders
All Female Male P value
Median (IQR) pain score (NRS) 8 (7, 9) 8 (7, 10) 8 (7, 9) 0.0005
Median (IQR) stiffness score (NRS) 8 (7, 9) 8 (7, 9) 8 (6, 9) 0.0049
Times of day when stiffness present (n, %)a
None 15 (2.3) 10 (2.5) 5 (2.0) 0.724
Morning 619 (95.2) 387 (95.6) 232 (94.7) 0.617
Lunchtime 368 (56.6) 227 (56.1) 141 (57.6) 0.708
Afternoon 357 (54.9) 219 (54.1) 138 (56.3) 0.576
Early evening 394 (60.6) 257 (63.5) 137 (55.9) 0.057
Late evening 446 (68.6) 288 (71.1) 158 (64.5) 0.078
During the night 467 (71.9) 302 (74.6) 165 (67.4) 0.047
Duration of morning stiffness (n, %) 0.491
None 12 (1.9) 8 (2.0) 4 (1.7)
1–15 minutes 31 (4.9) 16 (4.0) 15 (6.3)
16–45 minutes 69 (10.8) 41 (10.3) 28 (11.7)
46–60 minutes 72 (11.3) 50 (12.6) 22 (9.2)
> 1 hour 454 (71.2) 283 (71.1) 171 (71.3)
Able to raise both arms above head when first saw GP (n, %) 0.101
Yes 186 (28.8) 107 (26.6) 79 (32.5)
No 413 (64.0) 261 (64.9) 152 (62.6)
Don’t know 46 (7.1) 34 (8.5) 12 (4.9)
Use of prednisolone (n, %) 0.484
Yes 626 (96.9) 390 (96.5) 236 (97.5)
No 20 (3.1) 14 (3.5) 6 (2.5)
Other medications for PMR (n, %)a
Paracetamol 248 (37.9) 176 (43.2) 72 (29.2) <0.0001
Paracetamol and codeine 137 (21.0) 96 (23.6) 41 (16.6) 0.033
Non-steroidal anti-inflammatories 69 (10.6) 44 (10.8) 25 (10.1) 0.781
Strong prescription painkillers 86 (13.2) 62 (15.2) 24 (9.7) 0.043
Gastro-protection 332 (50.8) 210 (51.6) 122 (49.4) 0.585
Calcium and vitamin D 304 (46.5) 199 (48.9) 105 (42.5) 0.113
Osteoporosis treatments 170 (26.0) 119 (29.2) 51 (20.7) 0.015
Alternative therapies 26 (4.0) 20 (4.9) 6 (2.4) 0.115
Anti-depressants 55 (8.4) 47 (11.6) 8 (3.2) <0.0001
Other 100 (15.3) 55 (13.5) 45 (18.2) 0.105
aCan sum to >100 %, as respondents were able to choose more than one option. NRS numerical rating scales
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Comparison of the current study to those reported in
the literature suggests that overall levels of quality of life
[26, 27], depression [28, 29] and obesity [28, 29] are
similar to those expected in the population of this age,
and levels of daily alcohol consumption [29], current
smoking [8, 29] and anxiety are lower [28], although the
age structure of available comparator populations varies
between studies.
Fatigue was greater in the sample than the in general
US population [17], and physical functioning was much
better in the PMR population (n = 85) used to evaluate
change in patient-reported outcomes in PMR [30] where
the baseline median (IQR) mHAQ scores were much
higher (1.1 (0.8, 1.6)) than in this cohort, although the
scores at one week (0.4 (0.1, 0.8)) were similar to those
in the current study (0.4 (0.0, 1.0)). In part, this may re-
flect patient recall bias, with patients asked to recall
baseline disability or may reflect patients with a more
severe spectrum of disease being referred to specialist
services; however, reported duration of morning stiffness
and oral glucocorticoid use were similar between studies,
although this cohort had higher median (IQR) levels of
pain (8 (7, 9) on a numerical rating scale) compared to
this American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) sample [30].
Whilst this study has many strengths, including its size
and the availability of detailed information, it also has a
number of limitations that need to be considered. First,
the sample consists of patients with a GP diagnosis of
PMR. Diagnosing PMR is notoriously difficult, without a
single gold-standard diagnostic test to inform clinicians.
The recent ACR/EULAR classification criteria highlight
the challenges in diagnosing PMR, with 10 out of 128
people (7.8 %) diagnosed with PMR by specialists
subsequently having their diagnosis revised [30]. Al-
though rheumatology specialists may criticise the use of
GP diagnosis in this study, the majority of patients with
PMR are exclusively managed in the community and as
such GPs and rheumatologists are likely to encounter a
different spectrum of disease. In this study, we optimised
the diagnostic process by providing BSR guidance in the
consultation to support decision-making. Furthermore,
the rate of referral into the study of around 4.4 patients
per 10,000 per year in those aged over 40 years, is
similar to or below that previously reported in primary
care data (e.g. see [4]) providing further confidence in
our cohort.
A further limitation is the reliance on self-reported
data, and although questionnaires were mailed to partic-
ipants as soon as a diagnosis was made, some recall was
required. This is necessary for many of the constructs,
as they cannot be objectively measured (e.g. pain,
stiffness and quality of life), although for others (e.g.
medications) this is not necessarily the case. However,
additional information on the patient’s attribution of
their medication to PMR was possible through this use
of self-reported data. At future stages of the study, these
data will be linked to primary care consultation and pre-
scription records.
Conclusions
PMR has generally been considered to be a relatively
mild condition, associated with few other health compli-
cations. However, these patients report high levels of
pain and stiffness, which is prolonged after the morning
time, along with high levels of oral steroid use and poly-
pharmacy. It is also clear that women report worse
scores than men in almost all aspects of disease activity,
Fig. 1 The association between pain and stiffness scores (0–10 numerical rating scales (NRS)) by gender
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functioning and mental health. In addition, they are
more likely to report taking a range of medications in
addition to glucocorticoids for their PMR, notably strong
painkillers and anti-depressants.
Although this is the first study to characterise a cohort
of patients with incident PMR in primary care, further
work is needed to establish whether this group would all
be considered to have PMR if they visited a rheumatolo-
gist. Further studies will be required to determine
whether those with more depression or poorer physical
functioning have a worse prognosis over the course of
their PMR.
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